Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of Zoledronate in fracture prevention in osteopenic postmenopausal women.

Next Previous
Trial Profile

Efficacy of Zoledronate in fracture prevention in osteopenic postmenopausal women.

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Bone resorption; Fracture; Postmenopausal osteoporosis
  • Focus Therapeutic Use

Most Recent Events

  • 01 Apr 2020 Primary endpoint has been met (Time to first osteoporotic fracture in osteopenic postmenopausal women. Fracture assessed by verified xray reports or film. Timepoint: at six years from randomization) , according to Results published in the Calcified Tissue International
  • 19 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by Australian New Zealand Clinical Trials Registry.
  • 25 Jul 2009 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top